ReviewBioengineering (Basel, Switzerland)2023
Current Status of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2) in Maxillofacial Surgery: Should It Be Continued?
Review in Bioengineering (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- BMP-2 in oral-maxillofacial bone augmentation: a systematic review and meta-analysis.BMC oral health · 2026Pooled it
- Article
- Geometry-Dependent Osteogenic Performance of Demineralized Dentin Matrix as a Carrier for rhBMP-2.Tissue engineering and regenerative medicine · 2026Article
- Evaluation of teriparatide as a promoter of mandibular fracture healing: An observational clinical study.Chinese journal of traumatology = Zhonghua chuang shang za zhi · 2026Observational
- The role of bioactive molecules in enhancing bone healing in oral and maxillofacial surgery: a review of current approaches and future directions.Oral and maxillofacial surgery · 2026Review
- A novel mineral-organic bone adhesive promotes calvarial bone regeneration in microgravity conditions.NPJ microgravity · 2026Article
- Clinical Outcomes of rhBMP-2-Loaded Collagen Sponge for Alveolar Ridge Preservation: A Pilot Study.European journal of dentistry · 2026Article
- Bone regenerative capacity of the newly synthesized material QG3030: anJournal of periodontal & implant science · 2026Article
- Advanced Biomaterials for Craniofacial Tissue Regeneration: From Fundamental Mechanism to Translational Applications-A Scoping Review.Journal of functional biomaterials · 2026Review
- Engineering a BMP2-risedronate complex with sustained release for osteoporosis therapy.Archives of pharmacal research · 2025Article
- A Critical Review of Commercial Collagen-Based Scaffolds in Bone Regeneration: Functional Properties and Clinical Evidence from InfuseJournal of functional biomaterials · 2025Review
- Reducing Healing Period with DDM/rhBMP-2 Grafting for Early Loading in Dental Implant Surgery.Tissue engineering and regenerative medicine · 2025Article
- Demineralized Dentin Matrix Incorporated with rhBMP-2 Composite Graft for Treating Medication-Related Osteonecrosis of the Jaw.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Recombinant human bone morphogenetic protein-2 (rhBMP-2) has shown potential in maxillofacial surgery owing to its osteoinductive properties. However, concerns about its safety and high cost have limited its widespread use. This review presents the status of rhBMP-2 use in maxillofacial surgery, focusing on its clinical application, efficacy, safety, and limitations. Studies have demonstrated rhBMP-2's potential to reduce donor site morbidity and increase bone height in sinus and ridge augmentation; however, it may not outperform autogenous bone grafts. In medication-related osteonecrosis of the jaw treatment, rhBMP-2 has been applied adjunctively with promising results, although its long-term safety requires further investigation. However, in maxillofacial trauma, its application is limited to the restoration of large defects. Safety concerns include postoperative edema and the theoretical risk of carcinogenesis. Although postoperative edema is manageable, the link between rhBMP-2 and cancer remains unclear. The limitations include the lack of an ideal carrier, the high cost of rhBMP-2, and the absence of an optimal dosing regimen. In conclusion, rhBMP-2 is a promising graft material for maxillofacial surgery. However, it has not yet become the gold standard owing to safety and cost concerns. Further research is required to establish long-term safety, optimize dosing, and develop better carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.